Related Experiment Video
Updated: May 10, 2026
08:43
Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
Sclerostin: Another vascular calcification inhibitor?
Kathleen J Claes1, Liesbeth Viaene, Sam Heye
1Department of Nephrology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. kathleen.claes@uzleuven.be
The Journal of Clinical Endocrinology and Metabolism
|June 22, 2013
Summary
In patients with chronic kidney disease (CKD), higher sclerostin levels were initially linked to aortic calcification (AC). However, multivariate analysis revealed an inverse association, suggesting sclerostin may protect against vascular calcification progression.
Area of Science:
- Nephrology
- Cardiology
- Endocrinology
Background:
- Sclerostin, a Wnt antagonist from osteocytes, regulates bone turnover.
- Emerging evidence suggests Wnt pathway involvement in vascular calcification.
Purpose of the Study:
- To investigate the association between serum sclerostin levels and vascular calcification in non-dialysis chronic kidney disease (CKD) patients.
Main Methods:
- Cross-sectional analysis of 154 CKD patients.
- Aortic calcification (AC) assessed via lumbar X-ray.
- Serum sclerostin measured by ELISA, alongside cardiovascular risk factors.
Main Results:
- Aortic calcification present in 59% of patients.
- Higher sclerostin levels associated with older age, male sex, lower eGFR, and lower bone-specific alkaline phosphatase.
- Multivariate analysis identified lower sclerostin levels, older age, and cardiovascular history as independent determinants of AC.
Conclusions:
- Patients with CKD and AC showed higher sclerostin levels in initial analysis.
- Multivariate analysis revealed an inverse association between sclerostin and AC.
- Further research is needed to clarify sclerostin's role in vascular calcification.
Related Concept Videos
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...